COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lucentis (Ranibizumab) for Eales' Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00384449
Recruitment Status : Completed
First Posted : October 6, 2006
Results First Posted : June 11, 2019
Last Update Posted : June 11, 2019
Genentech, Inc.
Information provided by (Responsible Party):
Christina Flaxel, Oregon Health and Science University

Brief Summary:
The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.

Condition or disease Intervention/treatment Phase
Eales' Disease Drug: Ranibizumab Phase 2 Phase 3

Detailed Description:
This is a six-month study. Eligible subjects will receive one injection of the study drug into one eye for each of three months. Visual acuity, blood pressure and eye pressure will be tested. Subjects' retinas will be examined and thickness measured by optical coherence tomography (OCT). Safety visits will be scheduled for the week after the injections. The investigators will monitor the subjects' eyes for infection and inflammation. After the three-month treatment period, subjects will return to the clinic monthly for four follow-up visits. Procedures and tests that will be performed at the follow-up visits include visual acuity, a retinal exam including OCT, blood pressure, and eye pressure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease
Study Start Date : October 2006
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Lucentis (ranibizumab)
Lucentis (ranibizumab)
Drug: Ranibizumab
Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
Other Name: Lucentis

Primary Outcome Measures :
  1. Change in OCT Thickness. [ Time Frame: Baseline and 6 months ]
  2. Incidence and Severity of Ocular Adverse Events, as Identified by Eye Examination (Including Visual Acuity Testing) [ Time Frame: Monthly through Month 6 ]
  3. Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs [ Time Frame: Monthly through Month 6 ]
    No adverse events.

Secondary Outcome Measures :
  1. BCVA, as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters. [ Time Frame: Months 3,4,5 and 6 ]
  2. Incidence of Ocular and Non-ocular Adverse Events Evaluated Through Month 6. [ Time Frame: Monthly through Month 6 ]
    No adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  • Age > 21 years.
  • Disease related considerations:
  • For both treatment naïve and previously treated patients:

    • exclusion of all other causes of cystoid macular edema and retinal nonperfusion including branch or central vein occlusion, diabetic retinopathy, sickle retinopathy, sarcoidosis, systemic lupus and other collagen vascular diseases
    • chronic cystoid macular edema as noted clinically and on OCT 3 testing with persistent loss of visual acuity for 3 months or longer
    • if the eye has received prior treatment (including laser photocoagulation and steroids) a 30 day washout period will be required prior to treatment with Lucentis.
  • BCVA using ETDRS charts of 20/40 to 20/400 (Snellen equivalent) in the study eye.
  • OCT 3 central subfield > or = 250 on 2 separate readings in the central subfield.
  • Only one eye will be assessed in the study. If both eyes are eligible, the investigator will determine which eye will be entered into the study.

Exclusion Criteria:

  • Treatment for macular edema with intravitreal steroid or macugen within 30 days prior to enrollment in this study.
  • Previous vitrectomy within the past 6 months.
  • Previous cataract surgery within the preceding 12 months.
  • Active intraocular inflammation in the study eye.
  • Current vitreous hemorrhage in the study eye.
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
  • A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  • Participation in an investigational trial within 30 days of randomization that involved.
  • Treatment with any drug that has not received regulatory approval at the time of study entry.
  • Known allergy to any component of the study drug.
  • Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).
  • If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
  • Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months. Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.
  • Myocardial infarction, other cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 6 months prior to randomization.
  • Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomization.
  • Systemic anti-VEGF or pro-VEGF treatment used during the 6 months of the study.
  • Current treatment for active systemic infection.
  • History of recurrent significant infections or bacterial infections.
  • Subject is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the 6 months of the study.
  • Subjects meeting any of the following criteria will be excluded from the study:

    • Pregnancy (positive pregnancy test).
    • Prior enrollment in the study.
    • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
    • Participation in another simultaneous medical investigation or trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00384449

Layout table for location information
United States, Oregon
Casey Eye Institute
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Christina J. Flaxel, MD Casey Eye Institute, Oregon Health & Science University
Publications of Results:
Layout table for additonal information
Responsible Party: Christina Flaxel, Professor, Oregon Health and Science University Identifier: NCT00384449    
Other Study ID Numbers: FVF3849s
First Posted: October 6, 2006    Key Record Dates
Results First Posted: June 11, 2019
Last Update Posted: June 11, 2019
Last Verified: June 2019
Keywords provided by Christina Flaxel, Oregon Health and Science University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Vasculitis
Neovascularization, Pathologic
Pathologic Processes
Retinal Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents